Metabolic Syndrome Among HIV-Infected Patients

• DOI: 10.2337/diacare.28.1.132
• Publication Date: 2007-03-05T22:51:27Z
• Authors: Carlos Jericó; Hernando Knobel; Milagro Montero; Jordi Ordoñez-Ll...; Ana Guelar; Juan L. Gimeno; Pere Saballs; Jose L. López-Co...; Juan Pedro-Botet
• Keywords: Lopinavir; Stavudine; Ritonavir; Abdominal obesity

OBJECTIVE—To assess the prevalence in HIV-infected patients of metabolic syndrome as defined by National Cholesterol Education Program, i.e., three or more following components: abdominal obesity, hypertriglyceridemia, low HDL cholesterol, high blood pressure, and fasting glucose. RESEARCH DESIGN AND METHODS—In this cross-sectional study, 710 managed at outpatient clinic a tertiary hospital during 2003 completed study protocol consisting medical examination laboratory analysis after 12-h overnight fast. RESULTS—Metabolic was 17% increased from 5.1% among under age 30 years to 27.0% for those aged 50–59 years. Age (per 10-year increment) (odds ratio [OR] 1.41 [95% CI 1.12–1.77]), BMI (1.27 [1.19–1.36]), past present protease inhibitor exposure (2.96 [1.03–3.55] 4.18 [1.4–12.5], respectively) were independently associated with on logistic regression analysis. Furthermore, only stavudine (d4T) (1.74 [1.01–2.98]) lopinavir/ritonavir (2.46 [1.28–4.71]) adjustment BMI. CONCLUSIONS—The these is similar that previously reported uninfected individuals. Of specific concern association and, specifically, when individual antiretroviral drugs analyzed.